CYTOKINETICS INC
For the period ended Jun 30, 2024. Filed Aug 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 9, 2024
CYTK$56.18+1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
(In thousands, except share data) (Unaudited)
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Loss | Deficit | Equity (Deficit) | |
| Balance, December 31, 2023 | 101,637,922 | $102 | $1,725,823 | $(10) | $(2,112,238) | $(386,323) |
| Exercise of stock options | 1,466,359 | 2 | 29,530 | — | — | 29,532 |
| Vesting of restricted stock units | 695,140 | — | — | — | — | — |
| Shares withheld related to net share settlement of equity awards | (274,256) | — | (18,449) | — | — | (18,449) |
| Issuance of common stock under at-the-market offering, net of issuance costs | 1,237,460 | 1 | 93,639 | — | — | 93,640 |
| Exercise of warrants, net | 11,335 | — | — | — | — | — |
| Stock-based compensation | — | — | 21,612 | — | — | 21,612 |
| Other comprehensive loss | — | — | — | (529) | — | (529) |
| Net loss | — | — | — | — | (135,643) | (135,643) |
| Balance, March 31, 2024 | 104,773,960 | 105 | 1,852,155 | (539) | (2,247,881) | (396,160) |
| Exercise of stock options | 356,281 | — | 8,007 | — | — | 8,007 |
| Vesting of restricted stock units | 46,034 | — | — | — | — | — |
| Issuance of common stock under Employee Stock Purchase Plan | 93,857 | — | 2,678 | — | — | 2,678 |
| Issuance of common stock in public offering, net of issuance costs | 11,274,510 | 11 | 563,193 | — | — | 563,204 |
| Issuance of common stock in private placement, net of issuance costs | 980,392 | 1 | 49,999 | — | — | 50,000 |
| Stock-based compensation | — | — | 24,622 | — | — | 24,622 |
| Other comprehensive loss | — | — | — | (483) | — | (483) |
| Net loss | — | — | — | — | (143,318) | (143,318) |
| Balance, June 30, 2024 | 117,525,034 | $117 | $2,500,654 | $(1,022) | $(2,391,199) | $108,550 |
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Loss | Deficit | Deficit | |
| Balance, December 31, 2022 | 94,833,975 | $94 | $1,481,590 | $(3,590) | $(1,585,994) | $(107,900) |
| Exercise of stock options | 369,298 | — | 3,547 | — | — | 3,547 |
| Vesting of restricted stock units | 668,835 | — | — | — | — | — |
| Shares withheld related to net share settlement of equity awards | (262,829) | — | (10,517) | — | — | (10,517) |
| Stock-based compensation | — | — | 15,194 | — | — | 15,194 |
| Other comprehensive income | — | — | — | 1,945 | — | 1,945 |
| Net loss | — | — | — | — | (131,289) | (131,289) |
| Balance, March 31, 2023 | 95,609,279 | 94 | 1,489,814 | (1,645) | (1,717,283) | (229,020) |
| Exercise of stock options | 206,605 | — | 3,286 | — | — | 3,286 |
| Vesting of restricted stock units | 46,989 | — | — | — | — | — |
| Issuance of common stock under Employee Stock Purchase Plan | 74,937 | — | 2,401 | — | — | 2,401 |
| Stock-based compensation | — | — | 18,668 | — | — | 18,668 |
| Other comprehensive income | — | — | — | 187 | — | 187 |
| Net loss | — | — | — | — | (128,637) | (128,637) |
| Balance, June 30, 2023 | 95,937,810 | $94 | $1,514,169 | $(1,458) | $(1,845,920) | $(333,115) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.